¶ Spliceosome and Neurodegeneration
The spliceosome is the sophisticated cellular machinery responsible for pre-mRNA splicing, the process by which introns are removed and exons are joined to produce mature messenger RNA. Mutations in splicing factors and dysregulation of spliceosome function are increasingly recognized as causative or contributory factors in various neurodegenerative diseases.
flowchart TD
A["Primary Transcript"] --> B["Splicing"]
B --> C["Intron Removal"]
B --> D["Exon Ligation"]
C --> E["mRNA"]
D --> E
A --> F["RNA Editing"]
E --> G["Translation"]
G --> H["Protein"]
style A fill:#f3e5f5,stroke:#333
style H fill:#c8e6c9,stroke:#333
The spliceosome is a large ribonucleoprotein complex composed of five small nuclear ribonucleoproteins (snRNPs) - U1, U2, U4, U5, and U6 - along with numerous associated proteins. This molecular machine catalyzes the removal of introns from pre-mRNA through two transesterification reactions.
- U1 snRNP: Recognizes the 5' splice site
- U2 snRNP: Binds to the branch point sequence
- U4/U5/U6 tri-snRNP: Catalytic core of the spliceosome
- SF3B1: Component of U2 snRNP, mutated in some cancers and MDS
- U2AF: Auxiliary factor recognizing polypyrimidine tract and 3' splice site
- SRSF2: Serine/arginine-rich splicing factor 2
- hnRNPs: Heterogeneous nuclear ribonucleoproteins
The spliceosome undergoes a dynamic assembly process:
- E Complex: U1 snRNP binds 5' splice site; U2AF binds 3' splice site
- A Complex: U2 snRNP displaces U2AF and binds branch point
- B Complex: U4/U5/U6 tri-snRNP joins
- C Complex: Catalytic activation; internal rearrangements
- Post-catalytic: Spliceosome disassembles; snRNPs recycled
ALS is strongly linked to spliceosome dysfunction:
- TDP-43 (encoded by TARDBP) is an RNA/DNA-binding protein
- Forms characteristic inclusions in 97% of ALS cases
- Regulates splicing of numerous target transcripts
- Mutations cause familial ALS
- FUS (Fused in Sarcoma) is another RNA-binding protein
- Mutations cause ~5% of familial ALS
- Disrupts splicing of specific gene transcripts
- Affects stress response and RNA metabolism
- Heterogeneous nuclear ribonucleoprotein A1
- Mutations linked to ALS and inclusion body myopathy
- Affects splicing of transcripts involved in cytoskeletal function
- TDP-43 pathology in ~50% of FTD cases
- Overlap between ALS and FTD spectrum disorders
- Progranulin mutations affect splicing regulation
- Caused by deficiency in SMN1 (Survival Motor Neuron 1)
- SMN2 backup gene produces mostly non-functional transcripts
- Therapies targeting SMN2 splicing (Spinraza, Risdiplam) are effective
- PRPF31 mutations cause autosomal dominant RP
- Affects spliceosome function in photoreceptor cells
- Incomplete penetrance suggests modifier genes
- SF3B1 mutations are common in MDS
- Associated with ring sideroblasts
- Links splicing to mitochondrial function
In neurodegeneration, splicing factors can form pathological aggregates:
- Stress granules containing TDP-43 and FUS
- Sequestration of normal splicing factors
- Disruption of RNA processing homeostasis
Neurodegenerative diseases show characteristic splicing changes:
- Inclusion of cryptic exons
- Exon skipping events
- Altered isoform ratios
Splicing and transport are coupled:
- Defects in nuclear export
- Cytoplasmic mislocalization of transcripts
- Impaired local translation at synapses
Antisense oligonucleotides can modulate splicing:
- Spinraza (nusinersen): Modifies SMN2 splicing for SMA
- ASOs targeting toxic splice products: In development for ALS/FTD
- Splice-switching oligonucleotides: Currently in clinical trials
- splicing modulators in clinical trials
- Targeting specific splicing factors
- Modulating spliceosome assembly
- Viral delivery of corrected splicing factors
- CRISPR-based approaches to correct mutations
- Overexpression of protective splicing factors
- RNA-seq: Genome-wide splicing analysis
- CLIP-seq: Mapping RNA-protein interactions
- Minigene assays: Testing specific splicing events
- iPSC models: Patient-derived neurons
Emerging evidence links spliceosome dysfunction to AD pathogenesis.
¶ APP and Tau Splicing
Alternative splicing of APP and MAPT (tau) transcripts influences AD risk:
- APP splice variants containing exon 7 (KPI domain) are elevated in AD
- Tau exon 10 splicing produces 3R and 4R isoforms; dysregulation affects tau pathology
- splicing factors hnRNPs and SR proteins regulate these events
¶ Aβ and Splicing
Aβ oligomers can alter spliceosome function:
- Disruption of nuclear speckle organization
- Mislocalization of splicing factors
- Global changes in alternative splicing patterns
Spliceosome-targeted approaches in AD:
- Modulating splicing of APP to reduce toxic Aβ isoforms
- Correcting tau exon 10 splicing imbalances
- Restoring splicing factor homeostasis
PD research has uncovered connections to RNA processing:
- α-Synuclein can bind to RNA molecules
- Affects translation of specific mRNAs
- May disrupt ribosomal function
¶ LRRK2 and Splicing
LRRK2 mutations (common in familial PD):
- May affect splicing factor phosphorylation
- Alters alternative splicing of target transcripts
- Links kinase signaling to RNA processing
¶ PINK1 and Parkin
Mitophagy genes PINK1 and Parkin:
- Produce splice variants with altered function
- Splicing changes affect mitochondrial quality control
HD demonstrates dramatic splicing alterations:
- Expanded CAG repeats in HTT mRNA form toxic structures
- Aberrant splicing produces toxic peptide fragments
- Splicing factors sequestered into inclusions
RNA-seq studies reveal:
- Extensive exon skipping
- Cryptic exon inclusion
- Altered timing of splicing during development
Prion protein (PRNP) splicing is relevant:
- PRNP produces multiple splice variants
- Alternative isoforms may have protective roles
- Splicing dysregulation contributes to pathogenesis
SMA represents a success story for spliceosome-targeted therapy:
- Homozygous deletion or mutation of SMN1 causes SMA
- SMN protein essential for snRNP assembly
- Loss leads to widespread splicing defects
- SMN2 produces mostly non-functional transcripts
- ASO drugs redirect splicing to include exon 7
- Spinraza, Risdiplam, and Evrysdi are FDA-approved
flowchart TD
A["SMN2 Pre-mRNA"] --> B["Normal: Exon 7 skipped"]
B --> C["Non-functional protein"]
A --> D["ASO treatment"]
D --> E["Exon 7 included"]
E --> F["Functional SMN protein"]
F --> G["Rescue of motor neurons"]
style A fill:#ffebee
style F fill:#c8e6c9
PRPF31 mutations cause RP:
- PRPF31 is a spliceosome component
- Photoreceptor cells particularly vulnerable
- Incomplete penetrance suggests modifier effects
- Gene therapy to restore PRPF31 expression
- CRISPR correction of mutations
SF3B1 mutations link splicing to blood disorders:
¶ SF3B1 and MDS
- Most common splicing factor mutation in MDS
- Associated with ring sideroblasts
- Affects mitochondrial iron metabolism
- Splicing modulators in clinical trials
- Targeting altered splicing in malignant cells
The spliceosome assembly follows a tightly regulated pathway:
- E Complex (Early): U1 snRNP recognizes 5' splice site; U2AF binds 3' splice site and polypyrimidine tract
- A Complex (Prespliceosome): U2 snRNP displaces U2AF and binds branch point adenosine
- B Complex: U4/U5/U6 tri-snRNP joins the complex
- Bact Complex: Catalytic activation; U1 and U4 are released
- C Complex: First catalytic reaction; splice site cleavage
- Post-spliceosome: Lariat intermediate formed; exons ligated
- Disassembly: Spliceosome disassembles; snRNPs recycled
- Exon junction complex (EJC) deposits on mRNA
- NMD (nonsense-mediated decay) targets transcripts with premature stop codons
- Spliceosome checkpoints ensure fidelity
¶ Spliceosome and Stress Response
Stress granules and the spliceosome interact:
- Upon cellular stress, splicing factors redistribute
- TDP-43 and FUS localize to stress granules
- Prolonged stress leads to irreversible aggregation
- Preventing stress granule formation
- Disaggregating existing granules
- Modulating stress response pathways
- Over 50 mutations linked to ALS/FTD
- Predominantly in the C-terminal glycine-rich domain
- Affects RNA binding and splicing regulation
- Over 40 mutations cause familial ALS
- NLS domain mutations cause cytoplasmic mislocalization
- Affects stress granule dynamics
- Mutations cause inclusion body myopathy with Paget disease
- Affect prion-like aggregation properties
- Disrupt splicing of cytoskeletal genes
¶ SFPQ and Other Factors
- SFPQ (splicing factor, proline/glutamine-rich) affected in ALS
- Altered splicing of neuronal genes
- Links to synaptic function
Splicing signatures could serve as biomarkers:
- Distinct splicing patterns in patient blood/CSF
- Correlation with disease progression
- Potential for diagnostic use
- APP and tau splicing variants
- May predict disease progression
- Useful for clinical trials
- iPSC-derived neurons from patients
- CRISPR-corrected isogenic lines
- Overexpression/knockdown of splicing factors
- Transgenic TDP-43 mice
- FUS mutant models
- SMN-deficient models for SMA
- Recombinant spliceosome assembly
- Minigene reporters
- Single-molecule imaging
- Cell-type specific splicing patterns
- Heterogeneity in diseased brains
- Links to neuronal vulnerability
- Enhanced ASO delivery to CNS
- Small molecules targeting specific factors
- Combination approaches with other modalities
Chromatin state influences splice site choice:
- H3K36me3 promotes exon inclusion
- H3K4me3 marks active promoters affect first exon selection
- Histone readers like MRG15 connect chromatin to splicing
- Promoter methylation can alter splicing patterns
- Differential methylation in disease states
- Circular RNAs (circRNAs) can sponge splicing factors
- lncRNAs like MALAT1 regulate splicing factor activity
¶ Splicing and Synaptic Function
Neuronal activity modulates splicing:
- Calcium influx activates splicing regulators
- Immediate early genes often have regulated splice variants
- Synaptic plasticity requires specific isoforms
- Nova-1 regulates synaptic protein splicing
- Rbfox proteins control neuronal isoform expression
- Dysregulation affects synaptic function
Altered splicing contributes to:
- Autism spectrum disorders
- Schizophrenia
- Intellectual disability
- RNA sequencing for diagnostic confirmation
- Splicing reporter assays
- Patient-specific splice site analysis
- Genetic variants affecting drug response
- Splicing-modifying drugs require careful monitoring
Splicing-based biomarkers offer several advantages:
- Detectable in blood and CSF
- Reflect disease state
- Potentially predict treatment response
Aging affects spliceosome function:
- Global decline in splicing efficiency
- Increased cryptic splicing events
- Accumulation of splicing factor aggregates
Age-related splicing changes may:
- Increase neuronal vulnerability
- Reduce adaptive capacity
- Promote protein aggregation
The spliceosome consists of five core snRNPs:
U1 snRNP
- Composed of U1 snRNA and specific proteins
- Recognizes 5' splice site (GU)
- Contains U1-70K, U1-A, U1-C proteins
U2 snRNP
- U2 snRNA with SF3B1, SF3A proteins
- Binds branch point sequence
- Essential for spliceosome assembly
U4/U5/U6 tri-snRNP
- U4 and U6 are base-paired
- U5 contacts 5' and 3' exons
- Catalytic core of spliceosome
Over 200 proteins associate with the spliceosome:
- Splicing factors (SR proteins, hnRNPs)
- Kinases regulating splicing
- Helicases unwinding RNA
- Quality control proteins
The splicing reaction proceeds in two transesterification steps:
-
First step: 2'-OH of branch point attacks 5' splice site
- Forms lariat intermediate
- Releases 5' exon
-
Second step: 3'-OH of 5' exon attacks 3' splice site
- Joins exons
- Releases lariat intron
During neurodevelopment, splicing patterns shift dramatically:
- Embryonic isoforms replaced by adult forms
- Activity-dependent splicing factors increase
- Neuron-specific exons incorporated
NPCs show distinct splicing programs:
- Pluripotency factor splicing patterns
- Rapid transitions during differentiation
- Regulation by PTBP1 and PTBP2
Disrupted splicing during development can cause:
- Intellectual disability
- Autism spectrum disorders
- Developmental delays
¶ Splicing and Mitochondrial Function
Mitochondria have their own splicing machinery:
- Group I and II intron splicing
- tRNA processing
- RRNA modifications
Mitochondrial splicing defects affect:
- Energy production
- Calcium homeostasis
- Apoptosis regulation
Modulating splicing can improve mitochondrial function:
- Enhanced mitophagy
- Improved ATP production
- Reduced oxidative stress
¶ Spliceosome and Autophagy
Autophagy regulation involves splicing:
- Alternative splicing of autophagy genes
- Regulation of mitophagy receptors
- LC3 lipidation machinery
Spliceosome and autophagy interact:
- Damaged splicing factors removed by autophagy
- Stress granules cleared via autophagy
- Protein aggregate removal requires both
Common variants in splicing genes affect disease risk:
- hnRNPA1 variants in ALS
- FUS variants in FTD
- TARDBP variants in ALS/FTD
Splicing factor polymorphisms modify disease onset:
- Age of onset variations
- Progression rates
- Phenotypic presentations
Spliceosome components are highly conserved:
- Yeast to human conservation
- Essential splicing factors
- Disease-related mutations
Research benefits from diverse models:
- C. elegans for development
- Drosophila for genetics
- Zebrafish for development
- Mouse for disease modeling
Oxford Nanopore and PacBio enable:
- Full-length isoform detection
- Splice variant quantification
- Novel isoform discovery
Single-cell approaches reveal:
- Cell-type specific splicing
- Heterogeneity in disease
- Development trajectories
Next-generation RNA drugs:
- Engineered ASOs with improved CNS delivery
- siRNA for specific splice sites
- Circular RNAs as therapeutics
Drug-like molecules can:
- Modulate specific splicing factors
- Cross blood-brain barrier
- Be optimized for potency
Future therapies may combine:
- Splicing modulators with gene therapy
- ASOs with small molecules
- Multiple ASO targets
The spliceosome represents a critical nexus for understanding neurodegenerative diseases. Its central role in RNA processing, combined with the discovery of disease-causing mutations in splicing factors, makes it an attractive therapeutic target. From the success of SMN2-splicing modifiers in SMA to emerging ASO therapies for ALS, spliceosome-targeted approaches are translating from bench to bedside. Continued research into spliceosome biology promises new treatments for AD, PD, HD, and other neurodegenerative disorders.